Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liraglutide’s Future Uncertain: Panel Voices Concern Over Cancer And CV Risk

Executive Summary

Approval of Novo Nordisk's Victoza (liraglutide) for type 2 diabetes hinges on FDA's comfort with a safety database lacking on two fronts, an agency panel said April 2
Advertisement

Related Content

Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
Liraglutide Cancer Signal Puts Agency In Uncharted Review Territory
Liraglutide Cancer Signal Puts Agency In Uncharted Review Territory
Proxy War-Front Latest: Amylin, Vanda Rocked By Dissident Shareholders
Saxagliptin Cardiovascular Safety Affirmed, But Is It Approvable...And When?
Post-Marketing Trial Key To Saxagliptin Approval – And Commercial Potential
Post-Marketing Trial Key To Saxagliptin Approval – And Commercial Potential
Saxagliptin Cardiovascular Safety Affirmed, But Is It Approvable...And When?

Topics

Advertisement
UsernamePublicRestriction

Register

PS050914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel